SCHEMBL998975

SCHEMBL998975

CCN(CC)C(=O)c1ccc(O)nc1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 1/20 0.54
HSP90AA1 P07900 5/20 0.51
HSP90AB1 P08238 5/20 0.51
HPGD P15428 8/20 0.50
ALDH1A1 P00352 5/20 0.50
MAPT P10636 2/20 0.50
MLYCD O95822 2/20 0.49
LMNA P02545 4/20 0.47
CYP1A2 P05177 1/20 0.47
BLM P54132 1/20 0.47
RECQL P46063 1/20 0.47
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
TDP1 Q9NUW8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1308968 0.84 GRM5 (0.40) GRM5HSP90AA1HSP90AB1HPGDALDH1A1
SCHEMBL5429605 0.82 GRM5 (0.54) GRM5HSP90AA1HSP90AB1HPGDALDH1A1
SCHEMBL5420477 0.81 HPGD (0.53) GRM5HSP90AA1HSP90AB1HPGDALDH1A1
SCHEMBL5312194 0.81 SMN1; SMN2 (0.55) GRM5HSP90AA1HSP90AB1HPGDALDH1A1
SCHEMBL991484 0.81 GRM5 (0.59) GRM5HSP90AA1HSP90AB1HPGDALDH1A1
SCHEMBL12844304 0.81 GRM5 (0.52) GRM5HSP90AA1HSP90AB1HPGDALDH1A1
SCHEMBL3612518 0.79 KMT2A (0.50) HSP90AA1HPGDALDH1A1LMNACYP1A2
SCHEMBL5430899 0.79 HCAR3 (0.54) GRM5HSP90AA1HSP90AB1HPGDALDH1A1
SCHEMBL29133579 0.79 GRM5 (0.51) GRM5HSP90AA1HSP90AB1HPGDALDH1A1
SCHEMBL12776433 0.78 MLYCD (0.53) GRM5HSP90AA1HSP90AB1HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046724-A1 Expansible Biocompatible Coats Comprising a Biologically Active Substance AVIDAL VASCULAR GMBH (DE) 2011-02-24 US claimed
EP-2271396-A2 EXPANSIBLE BIOCOMPATIBLE COATS COMPRISING A BIOLOGICALLY ACTIVE SUBSTANCE Avidal Vascular Gmbh (DE) 2011-01-12 EP claimed
WO-2009121565-A2 EXPANSIBLE BIOCOMPATIBLE COATS COMPRISING A BIOLOGICALLY ACTIVE SUBSTANCE AVIDAL VASCULAR GMBH (DE) 2009-10-08 WO claimed
US-20110046724-A1 Expansible Biocompatible Coats Comprising a Biologically Active Substance AVIDAL VASCULAR GMBH (DE) 2011-02-24 US disclosed
EP-2271396-A2 EXPANSIBLE BIOCOMPATIBLE COATS COMPRISING A BIOLOGICALLY ACTIVE SUBSTANCE Avidal Vascular Gmbh (DE) 2011-01-12 EP disclosed
WO-2009121565-A2 EXPANSIBLE BIOCOMPATIBLE COATS COMPRISING A BIOLOGICALLY ACTIVE SUBSTANCE AVIDAL VASCULAR GMBH (DE) 2009-10-08 WO disclosed
US-20030031715-A1 Pharmaceutical applications of hydrotropic agents, polymers thereof, and hydrogels thereof PURDUE RESEARCH FOUNDATION 2003-02-13 US disclosed
WO-2002030466-A2 PHARMACEUTICAL APPLICATIONS OF HYDROTROPIC AGENTS, POLYMERS THEREOF, AND HYDROGELS THEREOF PURDUE RESEARCH FOUNDATION (US) 2002-04-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030031715-A1 Pharmaceutical applications of hydrotropic agents, polymers thereof, and hydrogels thereof HMGB2, HTT, ABCG2 GRM5 4501/4885HSP90AA1 23/4885HSP90AB1 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.